Results 1 to 10 of about 53,857 (331)
International Journal of Environmental Research and Public Health, 2021 Anxiolytics (N05B) are one of the most widely used pharmacological groups. This study aimed to analyze the progression of the consumption of anxiolytics (ATC classification: N05B) dispensed in pharmacies in Castile and Leon, Spain, from 2015 to 2020 ...
Miryam Sanchez Diaz +2 more
exaly +3 more sources
The Use of Antidepressants, Anxiolytics, Sedatives and Hypnotics in Europe: Focusing on Mental Health Care in Portugal and Prescribing in Older Patients [PDF]
International Journal of Environmental Research and Public Health, 2020 (1) Background: Mental disorders are a growing concern in the 21st century. The most prevalent common mental disorders include depression and anxiety. It is predicted that half of the population will at some point in their lives experience one or more ...
Marta Estrela +2 more
exaly +3 more sources
Neuroscience and Biobehavioral Reviews, 2020 This review introduces a research strategy that may radically transform the pursuit of new anxiolytics, via the use of human models of anxiety in healthy individuals. Despite enormous investments in developing novel pharmacological treatments for anxiety
Christian Grillon, Monique Ernst
exaly +2 more sources
Human Psychopharmacology, 2019 The aim of this study is to compare actual driving performance and skills related to driving of patients using benzodiazepine anxiolytics or hypnotics for at least 6 months to that of healthy controls.
Annemiek Vermeeren +2 more
exaly +2 more sources
Efficacy of lurasidone on anxiety symptoms in patients with schizophrenia: A pooled post hoc analysis of five randomized, placebo‐controlled trials [PDF]
PCN ReportsAim Comorbid anxiety disorders and their symptoms are common in schizophrenia and may occur before a relapse. The aim of this post hoc analysis is to investigate the efficacy of lurasidone on comorbid anxiety symptoms in patients with schizophrenia ...
Takahiro Nemoto +2 more
doaj +2 more sources
Antidepressant prescribing in transgender and nonbinary individuals diagnosed with gender dysphoria and mood or anxiety disorders [PDF]
Mental Health Clinician, 2023 Introduction: Transgender and nonbinary (TGNB) individuals are highly stigmatized members of society and are significantly at higher risk of having mood or anxiety-related disorders compared to non-TGNB individuals.
Casey M. Tiefenthaler, PharmD, BCPP +1 more
doaj +1 more source
Frontiers in Pharmacology, 2023 Introduction: The effectiveness and safety of the Chinese herbal medicine (CHM) Xiao Yao San (XYS) used for treating anxiety disorders are still unknown.
Yifan Wang +6 more
doaj +1 more source
Taiwanese Journal of Psychiatry, 2021 Background: The prevalence of prescriptions of anxiolytics and hypnotics/sedatives for child and adolescent patients with psychiatric illnesses is increasing over the world. No studies exist to focus on the prescription trends and patterns of anxiolytics
Shu- Wen Cheng +2 more
doaj +1 more source
Stress and arterial hypertension - from pathophysiology to pharmacology [PDF]
Srpski Arhiv za Celokupno Lekarstvo, 2021 Currently, arterial hypertension is the most massive chronic non-infectious disease of mankind. It may remain undiagnosed for years, provoking later complications, such as acute heart failure, cerebrovascular stroke, myocardial infarction, renal failure,
Nenezić Nemanja +5 more
doaj +1 more source
Neuroscience and Biobehavioral Reviews, 2022 The validity of widely used rodent behavioural tests of anxiety has been questioned, as they often fail to produce consistent results across independent replicate studies.
Marianna Rosso +7 more
semanticscholar +1 more source